Literature DB >> 2713959

Treatment of adult acute lymphoblastic leukaemia using an intensive chemotherapy protocol.

R Liang1, T K Chan, G T Chan, D Todd.   

Abstract

A total of 25 evaluable adult patients with acute lymphoblastic leukaemia (ALL) were treated with an intensive chemotherapy regime modified from the L17/L17M protocol of the Sloan-Kettering Hospital. There were 18 men and 7 women; their median age was 36 years (range, 13-78). Seven cases had L1 morphology and 18, L2. The immunophenotype was common-ALL in 10, null-ALL in 9, T-ALL in 4 and B-ALL in 1. Of the 25 patients, 14 (56%) achieved a complete remission (CR). The causes of induction failure were partial remission (PR) only in 7 (28%) and hypoplastic death in 4 (16%). Of the 14 CR patients, 11 (78.6%) relapsed. Five patients developed CNS disease. The median disease-free survival and overall survival were only 9 and 13 months, respectively. As the follow-up periods of the surviving patients were short, late relapses may still occur and the overall treatment result is likely to be worse on longer follow-up. The possible causes of this disappointing result are discussed.

Entities:  

Mesh:

Year:  1989        PMID: 2713959     DOI: 10.1007/BF00435841

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

Review 1.  Acute lymphoblastic leukemia in adults.

Authors:  B Clarkson; S Ellis; C Little; T Gee; Z Arlin; R Mertelsmann; M Andreeff; S Kempin; B Koziner; R Chaganti
Journal:  Semin Oncol       Date:  1985-06       Impact factor: 4.929

2.  Treatment of 218 adult acute lymphoblastic leukemias.

Authors:  D Fiere; J M Extra; B David; F Witz; J P Vernand; J A Gastaut; C Dauriac; J Pris; M Marty
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

3.  Confidence intervals for reporting results of clinical trials.

Authors:  R Simon
Journal:  Ann Intern Med       Date:  1986-09       Impact factor: 25.391

Review 4.  Acute lymphoblastic leukemia in adults: recent progress, future directions.

Authors:  D Hoelzer; R P Gale
Journal:  Semin Hematol       Date:  1987-01       Impact factor: 3.851

5.  Hybrid acute leukemia.

Authors:  I Ben-Bassat; R P Gale
Journal:  Leuk Res       Date:  1984       Impact factor: 3.156

6.  The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1981-04       Impact factor: 6.998

Review 7.  Lineage heterogeneity in acute leukaemia: acute mixed-lineage leukaemia and lineage switch.

Authors:  S A Stass; J Mirro
Journal:  Clin Haematol       Date:  1986-08

8.  Improved results of treatment of adult acute lymphoblastic leukemia.

Authors:  C A Linker; L J Levitt; M O'Donnell; C A Ries; M P Link; S J Forman; M J Farbstein
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

9.  Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen--a new intensive therapy protocol: a report from the Childrens Cancer Study Group.

Authors:  P G Steinherz; P Gaynon; D R Miller; G Reaman; A Bleyer; J Finklestein; R G Evans; P Meyers; L J Steinherz; H Sather
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

10.  Immunohistological subtypes of non-Hodgkin's lymphoma in Hong Kong Chinese.

Authors:  F C Ho; S L Loke; P K Hui; D Todd
Journal:  Pathology       Date:  1986-10       Impact factor: 5.306

View more
  1 in total

1.  Acute lymphoblastic leukaemia in adults: immunological subtypes and clinical features at presentation.

Authors:  M B van't Veer; W L van Putten; L F Verdonck; G J Ossenkoppele; B Löwenberg; J C Kluin-Nelemans; P W Wijermans; H C Schouten; W Sizoo; A W Dekker
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.